Join

Compare · MEDP vs SYNH

MEDP vs SYNH

Side-by-side comparison of Medpace Holdings Inc. (MEDP) and Syneos Health Inc. (SYNH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MEDP and SYNH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
  • MEDP is the larger of the two at $12.97B, about 1.4x SYNH ($9.19B).
  • MEDP has hit the wire 10 times in the past 4 weeks while SYNH has been quiet.
  • MEDP has more recent analyst coverage (25 ratings vs 19 for SYNH).
MetricMEDPSYNH
Company
Medpace Holdings Inc.
Syneos Health Inc.
Price
$454.36-0.89%
$42.98+0.01%
Market cap
$12.97B
$9.19B
1M return
+6.48%
-
1Y return
+52.44%
-
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Commercial Physical & Biological Resarch
Exchange
NASDAQ
NASDAQ
IPO
2016
2014
News (4w)
10
0
Recent ratings
25
19
MEDP

Medpace Holdings Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

SYNH

Syneos Health Inc.

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina

Latest MEDP

Latest SYNH